Genmab A (GMAB) EPS (Diluted) (2018 - 2026)
Powered by 
Analysis
Genmab A (GMAB) EPS (Diluted) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 4.37 |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 4.31 |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 12.23 |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -1.96 |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 7.15 |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 1.19 |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -0.40 |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | 4.58 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.58 |
| Mar 31, 2026 | 90.63 |
| Sep 30, 2025 | 88.95 |
| Jun 30, 2025 | 12.42 |
| Mar 31, 2025 | 81.91 |
| Sep 30, 2024 | 46.50 |
| Jun 30, 2024 | 3.02 |
| Mar 31, 2024 | 47.53 |
| Dec 31, 2023 | -38.51 |
| Sep 30, 2023 | 45.02 |
| Jun 30, 2023 | 2.53 |
| Mar 31, 2023 | 40.70 |
| Dec 31, 2022 | 1.15 |
| Sep 30, 2022 | 39.80 |
| Jun 30, 2022 | 3.99 |
| Dec 31, 2021 | -35.68 |
| Sep 30, 2021 | 38.71 |
| Jun 30, 2021 | 2.66 |
| Mar 31, 2021 | 22.38 |
| Dec 31, 2020 | 26.28 |